Altaris to acquire Simulations Plus in $375m all-cash deal
Completion of the transaction is expected in the fourth quarter of 2026.
Drug Manufacturers
University of Edinburgh develops cell therapy for liver disease
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
GSK and SBP Group team up to advance bepirovirsen launch in China
Aligos and Xiamen Amoytop sign deal for HBV therapy
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CordenPharma leases space at Flatiron Park for peptides development
Europe’s pharma trade with the US remains critical despite tariff turmoil
